Skip to main content
. 2020 Jun 12;11:885. doi: 10.3389/fphar.2020.00885

Figure 2.

Figure 2

Administration of PR-957 reduces Ang II–induced cardiac hypertrophy in vivo. (A) Representative echocardiography images of Ang II–infused mice in the presence or absence of PR-957 for 2 weeks (top). Quantitative analysis of left ventricular (LV) ejection fraction (EF%, bottom, n = 5). (B) Representative images of heart size photographed with a stereomicroscope (top). Scale bar, 200 mm. Ratios of heart weight/body weight (HW/BW) and heart weight/tibial length (HW/TL, bottom, n = 5). (C) LV sections were stained with wheat germ agglutinin (WGA) to demarcate the cell boundaries (left). Scale bar, 100 μm. Quantification of the relative myocyte cross-sectional area (200 cells counted per heart) (right, n = 5). (D) Quantitative real-time polymerase chain reaction analysis of the mRNA levels of ANF and β-MHC (right, n = 5). Data are expressed as mean ± SEM, and n represents the number of animals per group. *P < 0.05, **P < 0.01 vs. saline; #P < 0.05 vs. Ang II.